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Induced Expression of Insulin-like Growth Factor-1 by
Amniotic Membrane-Conditioned Medium in Cultured
Human Corneal Epithelial Cells
Joon H. Lee,1 Ik Hee Ryu,1 Eung Kweon Kim,1,2 Jong Eun Lee,2,3 SoonWon Hong,4 and
Hyung Keun Lee1
PURPOSE. To determine the effect of amniotic membrane–con-
ditioned medium (AMCM), via insulin-like growth factor
(IGF)-1 induction, on human corneal epithelial cell (HCEC)
proliferation.
METHODS. HCECs were cultured from corneal limbal tissue with
supplemented hormonal epithelial medium (SHEM). After ad-
ministration of AMCM, cell proliferation was evaluated with an
MTT assay and DNA synthesis with methyl-[3H]-thymidine in-
corporation assay. RT-PCR and Western immunoblot analyses
were performed, to determine potential inducible factors that
may be associated with AMCM-induced cell proliferation. Neu-
tralizing anti-IGF-1 antibody and small interfering (si)RNA were
also used to clarify the role of IGF-1 in AMCM-induced HCEC
proliferation.
RESULTS. HCEC proliferation increased after AMCM treatment.
Of the cytokines known to be associated with HCEC prolifer-
ation, only IGF-1 expression was upregulated in response to
AMCM in a dose- and time-dependent manner. The IGF-1 in-
duction effect was found on both AMCM from live AM and
from cryopreserved AM. HCEC proliferation was also increased
by addition of exogenous IGF-1. AMCM-induced HCEC prolif-
eration was inhibited in the presence of neutralizing anti-IGF-1
antibody and IGF-1 siRNA. Finally, Akt phosphorylation was
increased in HCECs after AMCM treatment and was inhibited
by IGF-1 siRNA.
CONCLUSIONS. IGF-1 is induced by AMCM during HCEC prolif-
eration, and this induction may play an important role in the
amniotic membrane during HCEC proliferation and migration
in several intractable corneal epithelial defects. (Invest Oph-
thalmol Vis Sci. 2006;47:864–872) DOI:10.1167/iovs.05-0596
The ocular surface serves as a key barrier that protects theinternal structures of the eye from the external environ-
ment. The integrity of the ocular surface and the healing of
corneal wounds depend on a delicate balance among cellular
proliferation, differentiation, migration, and apoptosis.1 By
their regulation of these functions, a variety of growth factors
produced by the corneal epithelium, stroma, and endothelium
play a vital role in the maintenance of normal corneal func-
tion.2,3 As yet, the soluble factors and intracellular signaling
pathways involved in this process are not fully understood.
Several factors may have the potential to modulate cell migra-
tion and growth and may therefore be involved in wound
healing, including insulin-like growth factor (IGF)-1, insulin,
substance P (SP), epidermal growth factor (EGF), hepatocyte
growth factor (HGF), keratinocyte growth factor (KGF), and
nerve growth factor (NGF).1,4–6
IGF-1 and its receptors have been identified in many tissues
throughout the body, and they have been demonstrated to play
an important role in cell proliferation and differentiation.7,8 In
rabbit and rat cornea, IGF-1 has been demonstrated to stimu-
late corneal epithelial migration in both organ culture and in
vivo models.5,9 However, few studies have examined the rela-
tionship between cell proliferation and IGF-1. Furthermore,
the effects of IGF-1 on human corneal epithelial cell (HCEC)
proliferation and migration have not yet been fully elucidated.
The amniotic membrane (AM) is the innermost layer of the
fetal membranes and consists of a simple epithelium, a thick
basement membrane, and an avascular stroma. When appro-
priately procured, processed, and preserved, AM has been
successfully used as a substrate replacement for ocular surface
reconstruction and is effective in the treatment of many severe
and progressive epithelial defects, including neurotrophic cor-
neal ulcers.10–14 Recently, the underlying action mechanism
explaining how AM transplantation works during ocular sur-
face reconstruction has been reviewed.15 Although one plau-
sible mechanism explaining how AM may promote corneal
epithelial growth is to release nerve growth factor,16 few
studies have demonstrated whether the AM stimulates cyto-
kines, thereby facilitating wound healing.
In this study, we investigated the effects of AM on HCEC
proliferation, by using AM-conditioned medium (AMCM),
which contains substances and growth factors released from
AM. We also assessed whether any cytokines play a role in
AM-induced HCEC proliferation.
MATERIALS AND METHODS
Chemical Reagents and Cell Culture Media
Dulbecco’s modified eagle medium (DMEM), F-12 nutrient mixture,
fetal bovine serum (FBS), HEPES buffer, amphotericin B, and gentami-
cin were purchased from Invitrogen-Gibco (Grand Island, NY). Other
reagents and chemicals, including mouse-derived EGF, cholera-toxin
(subunit A), dimethyl sulfoxide (DMSO), hydrocortisone, transferrin,
and human insulin were purchased from Sigma-Aldrich Chemical Co.
(St. Louis, MO). Dispase II was obtained from Roche Applied Science
(Mannheim, Germany). Plastic cell culture dishes (35 and 60 mm),
polyester membrane inserts (six-well, pore size 0.4 m; Transwell), a
96-well plate, and 15- and 50-mL sterile centrifuge conical tubes were
purchased from Corning-Costar (Acton, MA). Affinity-purified goat
polyclonal antibodies against human IGF-1, keratinocyte growth factor
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(KGF), EGF, and platelet-derived growth factor (PDGF) were pur-
chased from R&D Systems, Inc. (Minneapolis, MN). The horseradish
peroxidase (HRP)-conjugated secondary antibody was obtained from
Dako (Glostrup, Denmark).
Preparation of Human AM and AMCM
Human tissues were handled according to the tenets of the Declaration
of Helsinki, with the approval of institutional review boards (IRBs).
Human placenta was obtained from an elective Cesarean section per-
formed on a seronegative (human immunodeficiency virus, human
hepatitis type B and C, and syphilis) woman. Under a laminar flow
hood, the placenta was cleansed of blood clots with sterile phosphate-
buffered saline (PBS) solution containing 50 g/mL penicillin, 50
g/mL streptomycin, and 2.5 g/mL amphotericin B. After the mem-
brane was cleansed three times with PBS, it was cut into several
100-mm
2
pieces. For cryopreservation, some membrane pieces were
then attached to a nitrocellulose membrane (Immobilon-NC; Millipore,
Billerica, MA), by placing the epithelial side up. The membrane was
stored at 20°C in DMEM containing glycerin (Invitrogen-Life Tech-
nology Inc., Gaithersburg, MD) in a ratio of 1:1 (vol/vol) for 2 weeks.
Other fresh AM pieces were incubated in 10 mL DMEM without FBS in
a 100-mm culture dish for 24 hours at 37°C in 95% humidity and 5%
CO2. The medium was then collected and preserved at 70°C before
use. AMCM was obtained from cryopreserved AM by thawing and
washing the cryopreserved amniotic membrane, which was stored for
2 weeks at 20°C three times with sterile PBS. The membrane was
then cultured in the same medium, temperature, and humidity to
obtain the AMCM from fresh AM for 24 hours. The collected medium
was also preserved at 70°C.
Human Limbal Explant Culture
Human corneal limbal tissue was harvested from the donor corneal
button after keratoplasty. The corneal limbal tissue was washed three
times with DMEM containing 50 g/mL gentamicin and 1.25 g/mL
amphotericin B. After removal of excessive conjunctiva, sclera, and iris
tissue, the remaining tissue was placed in a culture dish and exposed
for 1 hour to 1.2 U/mL dispase II in Mg2- and Ca2-free solution at
37°C in 95% humidity and 5% CO2. The epithelial tissue was separated
from the rest of the tissue and cut into 2.0-mm2 tissue sections with a
no. 15 blade and scissors. The segmented epithelial tissue was placed
on the upper chamber of a cell-migration culture dish (Transwell;
Corning-Costar), which has a lower chamber containing 3T3 fibro-
blasts, and was cultured in supplemental hormonal epithelial medium
(SHEM) made of an equal volume of HEPES-buffered DMEM containing
bicarbonate and Ham’s F12 supplemented with 10% FBS, 0.5% DMSO,
50 g/mL gentamicin, 1.25 g/mL amphotericin B, 2 ng/mL mouse
EGF, 5 g/mL insulin, 5 g/mL transferrin, 0.5 mg/mL hydrocortisone,
and 30 ng/mL cholera toxin. Human corneal limbal epithelial cells
were maintained at 37°C under 95% humidity and 5% CO2. The me-
dium was changed every other day, and cell outgrowth was monitored
daily for 3 weeks with inverted phase microscopy. When the cultured
corneal epithelium was 80% to 90% confluent, the cells were subcul-
tured with 0.25% trypsin and 5.0 mM EDTA with a 1:3 split. In all
experiments using cultured human corneal epithelium, we used the
second- and third-passage cells.
MTT HCEC Proliferation Assay
Confluent cultures of HCECs were trypsinized and plated into 96-well
plates at a density of 2  105 cells/mL and allowed to attach for 48
hours at 37°C. Then, a cell-proliferation assay was performed. After the
medium was removed, and cells were washed twice in PBS, HCECs
were serum-fasted for 12 hours. The cells were then incubated with
AMCM (10, 50 L/mL) or IGF-1 (10 or 50 ng/mL) in serum-free DMEM
for 12, 24, and 48 hours. The cell proliferation assay was performed by
using the MTT colorimetric assay system, which measures the reduc-
tion of the tetrazolin component (i.e., MTT) into an insoluble formazan
product by the mitochondria of viable cells. One hour before cell
harvest, the culture medium was replaced with serum-free medium,
and 100 L MTT solution (5 mg/mL in PBS) was added to each well.
After a 1-hour incubation, the medium was replaced by 0.4 mL acidic
isopropanol (0.04 M HCl in absolute isopropanol) to solubilize the
colored crystals. The samples were read using an ELISA plate reader
(Labsystems Multiskan MCC/340; Fisher Scientific, Pittsburgh, PA) at a
wavelength of 570 nm with background subtraction at 650 nm. The
FIGURE 1. The effect of AMCM on HCEC proliferation. (A) HCECs
were cultured with serum- and growth factor–free medium for 12
hours and then treated with AMCM (10 or 50 L/mL) or left untreated.
Cell proliferation was measured with the MTT assay for 48 hours. (B)
AMCM induced DNA synthesis. For the methyl-[3H]-thymidine incor-
porated assays, the HCECs were incubated with SHEM for 24 hours,
with or without AMCM (10 or 50 L/mL). Before stimulation with
AMCM or no stimulation, cells were starved of serum and growth
factors for 12 hours. After 22 hours with or without AMCM, the cells
were labeled with 5 Ci methyl-[3H]-thymidine for 2 hours (*P  0.05,
†P  0.01).
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amount of color produced that normalized with the background is
directly proportional to the number of viable cells and is represented
as the proliferation index. For proliferation inhibition assay, 1 hour
before treatment of AMCM, 10 ng/mL of neutralizing anti-IGF-1 anti-
body was inoculated. Then, the proliferation assay was as just de-
scribed. All the assays were repeated three times with triplicate sam-
ples.
Determination of DNA Synthesis
with Methyl-[3H]-Thymidine
Cells were incubated in serum- and growth factor-free DMEM, with or
without AMCM (10 or 50 L/mL) and IGF-1 (10 or 50 ng/mL), up to 24
hours. One hour before harvesting of the cells, the medium was then
replaced with serum-free DMEM with 5 Ci methyl-[3H]-thymidine (90
Ci/mmol; GE Healthcare, Buckinghamshire, UK). Labeling was termi-
nated by washing the cells with ice-cold PBS three times, followed by
the addition of 0.5 mL of dissolution buffer (25 mM HEPES [pH 7.5] and
0.1% Triton X-100) and 5 L of 2% sodium deoxycholate. After cells
were lysed, the lysate was collected into a 1.5-mL microfuge tube,
precipitated with trichloroacetic acid to a final concentration of 10%,
and centrifuged at 14,000 rpm for 10 minutes at 4°C. The pellet was
then washed with 400 L of 10% trichloroacetic acid, dissolved in 200
L of 0.2 M NaOH and counted with a  counter (Beckman Instru-
ments, Montreal, Quebec, Canada).
Determination of IGF-1, EGF, PDGF, and KGF
Induction and Akt Phosphorylation in HCECs
The cultured HCECs were 80% to 90% confluent in all six-well migra-
tion chambers (Transwell; Corning-Costar). The lower chamber con-
taining 3T3 fibroblasts was discarded, and the HCECs were washed
with PBS. The lower chamber was then exchanged with a new one
without a fibroblast feeder layer and was incubated for various times in
serum- and growth factor–free DMEM, with or without AMCM (10 or
50 L/mL) from live AM or cryopreserved AM. Cells were then washed
with ice-cold PBS and lysed with cell lysis buffer (20 mM HEPES [pH
7.2], 10% glycerol, 10 mM Na3VO4, 50 mM NaF, 1 mM phenylmethyl-
sulfonyl fluoride [PMSF], 0.1 mM dithiothreitol, 1 g/mL leupeptin, 1
g/mL pepstatin, and 1% Triton X-100) on ice for 30 minutes. The
lysate was subjected to sonication, and the cell homogenates were
then centrifuged at 15,000g for 10 minutes. Protein concentration of
the resultant supernatant was assessed with a Bradford reagent.
Western Immunoblot Analysis
Twenty micrograms of protein were electrophoresed. After cell sample
preparation (as described earlier), Laemmli sample buffer was added,
and the samples were boiled for 5 minutes. Proteins were separated by
SDS-PAGE (8% gels) and transferred to a polyvinylidene fluoride (PVDF;
Millipore) transfer membrane. Antibodies against IGF-1 (1:1000), EGF
FIGURE 2. Western immunoblot anal-
ysis of IGF-1, PDGF, KGF, and EGF
expression in HCECs after 10 L/mL
AMCM treatment. Twelve hours after
treatment with AMCM or no treat-
ment, expression of these growth fac-
tors in HCECs was evaluated with
Western immunoblot analysis on cell
lysates. IGF-1 expression was only sig-
nificantly increased after AMCM treat-
ment (first panel and densitometry;
*P  0.05, compared with control).
However, expression of PDGF, KGF,
and EGF did not significantly differ be-
tween control and AMCM-treated
cells.
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(1:500), PDGF (1:1000), and KGF (1:500) were used at various dilu-
tions. Phosphorylation of Akt, a major cellular substrate of phospho-
inositide 3-kinase (PI3-K), was determined with a phospho-Akt-specific
antibody. Secondary antibodies were conjugated to HRP. Immunore-
active bands were visualized using the enhanced chemiluminescence
method (ECL kit; GE Healthcare).
RT-PCR for IGF-1 Expression in HCECs after
AMCM Treatment
Twelve hours after the addition of either 10 or 50 L/mL AMCM to
cultured HCECs in serum- and growth factor-free medium, total RNA
was isolated (SV Total RNA Isolation System; Promega, Madison, WI),
according to the manufacturer’s instructions. The concentration and
purity of RNA was determined by spectrophotometric measurement
(Gene Quant II; Pharmacia Biotech, Cambridge, UK). Total RNA was
converted into cDNA by A first-strand synthesis system (Superscript;
Invitrogen-Gibco) under the following conditions: 0.4 M each primer,
0.2 mM deoxynucleoside triphosphate mixture (Applied Biosystems,
Inc. [ABI], Foster City, CA), 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5
mM MgCl2, and 1 unit Taq polymerase (ABI). The reaction mixtures
were incubated in a thermal controller (Model TPC-100; MJ Research,
Watertown, MA) for 35 cycles of denaturation for 45 seconds at 95°C,
annealing for 1 minute at 58°C, and extension for 45 seconds at 72°C.
The quantity of the amplified products was analyzed with an image-
documentation system (ImageMaster VDS; Pharmacia Biotech Inc.,
Uppsala, Sweden). The primer sequences specific to IGF-1 were 5-
GAG CCT GCG CAA TGG AAT AAA GTC-3 (forward) and 5-CGG TGG
CAT GTC ACT CTT CAC TC-3 (reverse). This primer sequence was
already used to detect IGF-1 in a previous study.17 The band area of
IGF-1 was normalized with 18s RNA from each sample, and the IGF-1
mRNA level was then estimated.
IGF-1 Small Interfering RNA
IGF-1 small interfering (siRNA; Ambion, Austin, TX) transfection was
performed according to the manufacturer’s instructions. Briefly, cells
were incubated until they reached 60% confluence, the transfection
reagent (siPORT Amine; Ambion) was diluted into serum-free DMEM
medium and incubated for 20 minutes at room temperature. The
diluted transfection reagent was combined and mixed with the IGF-1
siRNA. The mixture was incubated for 20 minutes at room temperature
to allow transfection complexes to form. The newly formed transfec-
tion complexes were then dispensed onto the cells for a final RNA
concentration of 100 nM. Without swirling, the plate was gently
rocked back and forth to distribute the complexes evenly. After a
16-hour incubation, the transfected cells were further incubated in
serum-free DMEM for 6 hours. AMCM (200 L/mL) was added to the
transfected cells. For Western blot analysis, cells were harvested 1 hour
after AMCM treatment. For the proliferation assay, cell growth was
FIGURE 3. (A) Expression of IGF-1 mRNA in HCECs, as determined by
RT-PCR after treatment with AMCM or no treatment (lane M: marker;
lane 1: serum-free medium; lane 2: 10 L/mL AMCM; lane 3: 50
L/mL AMCM). (B) Densitometry showed that expression of IGF-1
mRNA (635 kb) was increased after treatment with 50 L/mL AMCM
compared with the control.
FIGURE 4. Expression of IGF-1 in HCECs after AMCM treatment
changed in a dose-dependent manner. Twenty-four hours after treat-
ment with 10 or 50 L/mL AMCM or no treatment, the cell lysate was
subjected to 8% SDS-PAGE (A) under reduced conditions and trans-
ferred to a PVDF membrane, followed by immunoblot analysis with
IGF-1 antibody. IGF-1 expression increased in a dose-dependent man-
ner (B).
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measured 24 hours after AMCM treatment by the MTT proliferation
assay (Roche Molecular Biochemicals).
Statistical Analysis
Statistical analysis was performed on computer (SPSS ver. 11.0; SPSS
Inc., Chicago, IL). Cell proliferation, DNA contents, and densitometry
results were analyzed with the t-test or the Mann-Whitney test. Corre-
lations between parameters were analyzed with the Pearson test. All
tests were made assuming a level of statistical significance of P  0.05.
RESULTS
Effects of AMCM on HCEC Proliferation
and Migration
HCEC proliferation was determined by MTT assay and pre-
sented as a percent of the number of control cells at each
AMCM concentration (Fig. 1A). HCEC proliferation was in-
creased by AMCM in a dose- and time-dependent manner. No
statistically significant difference in cell proliferation was ob-
served between the control and AMCM-treated groups after 3
hours. However, at 6 hours, proliferation of HCECs treated
with 50 L/mL AMCM was significantly increased compared
with control cells but not with HCECs treated with 10 L/mL
AMCM. At 12 hours, proliferation was also significantly in-
creased in HCECs treated with 10 L/mL AMCM compared
with control cells. Proliferation of HCECs grown in AMCM
remained increased compared with the control at the 48-hour
time-point. At 48 hours, the population of HCECs grown in the
presence of 50 L/mL AMCM was twice as dense as the control
population.
The total DNA content was assayed using methyl-[3H]-thy-
midine incorporation into DNA. Twenty-four hours after treat-
ment of AMCM, total DNA content was increased by 2.4 times
compared with serum- and growth factor-free control (Fig. 1B).
It is possible that a potential artifact caused by radiation dam-
age hampers the results when cell proliferation is determined
with [3H]-thymidine.18 Therefore, we evaluated the correlation
of both methods—MTT assay and methyl-[3H]-thymidine incor-
poration DNA synthesis—and the correlation coefficient (r)
was 0.89 (P  0.001, Pearson correlation coefficient).
Identification of Possible Factors Responsible for
the Proliferative Effects of AMCM in HCECs
To determine whether cytokine expression in HCECs is in-
duced by AMCM, we performed Western immunoblot analysis
to detect the presence of IGF-1, PDGF, EGF, and KGF in HCEC
lysates after treatment with 10 L/mL AMCM. Only IGF-1
expression was significantly increased compared with control
cells (Fig. 2). The expression of KGF, EGF, and PDGF did not
differ between the serum-free control and AMCM-treated cells.
RT-PCR for Detection of IGF-1 mRNA in HCECs
after AMCM Treatment
To determine whether the increased production of IGF-1 in
AMCM-treated HCECs is regulated at the mRNA level, RT-PCR
was performed. Using an IGF-1-specific primer, we found that
IGF-1 mRNA expression was upregulated in AMCM-treated
cells (Fig. 3, lanes 2, 3) compared with control cells (Fig. 3,
lane 1). AMCM appeared to induce HCEC IGF-1 mRNA expres-
sion in a dose-dependent manner. These results suggest that
AMCM-induced IGF-1 production in HCECs is, at least in part,
regulated at the mRNA level.
Western Immunoblot Analysis to Detect IGF-1 in
HCEC Lysates after AMCM Treatment
To assess further the AMCM-induced expression of IGF-in
HCECs, we next investigated IGF-1 protein expression at vari-
ous AMCM concentrations and at various time points. IGF-1
expression was increased in a dose- and time- dependent man-
ner. At 24 hours after AMCM treatment, IGF-1 expression
FIGURE 5. Change of IGF-1 expres-
sion in HCECs after treatment with
50 L/mL AMCM or no treatment in
a time-dependent manner. Twelve
hours after serum and growth factor
starvation, the medium was changed
to serum-free medium with or with-
out 50 L/mL of AMCM. The IGF-1
expression was evaluated with West-
ern immunoblot analysis for 0, 6, 12,
and 24 hours (A) and the expression
was compared with densitometry
(B). The protein preparation, electro-
phoresis, and PVDF membrane trans-
fer conditions were the same as for
the dose-dependent condition (Fig.
4). IGF-1 expression in AMCM-
treated cells increased beginning at 6
hours after treatment and peaked at
12 hours. (*P  0.05, †P  0.01,
compared with the baseline).
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increased in a dose-dependent manner until the AMCM con-
centration reached 50 L/mL (Fig. 4).
To investigate when the IGF-1 was induced by AMCM in
HCECs, we determined the expression of IGF-1 in a time
sequence. In the serum- and growth factor–free control, the
IGF-1 expression was not significantly different from the base-
line after 24 hours (Fig. 5A). In the AMCM-treated cells (50
L/mL), the expression of IGF-1 was not different from the
baseline until 2 hours. At 6 hours, IGF-1 expression started to
increase in AMCM-treated HCECs and was higher than baseline.
This increased expression of IGF-1 was observed until 24 hours
after AMCM treatment (Figs. 5A, 5B).
To determine whether the cryopreserved AM could also
induce the IGF-1 from HCECs, we compared the IGF-1 induc-
tion effect of AMCM between live and cryopreserved AM.
Twelve hours after treatment with AMCM from either live or
cryopreserved AM, IGF-1 was induced in the HCECs in both
conditions (Fig. 6). Densitometry for IGF-1 did not show a
significant difference.
IGF-1-Induced HCEC Proliferation
We next tested whether introduction of exogenous IGF-1
could enhance the cell proliferation and DNA content in
HCECs. At 24 hours, HCEC proliferation increased in response
to IGF-1 in a dose-dependent manner. Treatment with 50
ng/mL increased cell proliferation twofold compared with the
control (Fig. 7A). The DNA synthesis was also increased by
treatment of IGF-1 (Fig. 7B). The cellular proliferative effect of
IGF-1 in HCECs was well correlated with the increment of DNA
synthesis (r  0.92, P  0.0001; Pearson correlation coeffi-
cient).
FIGURE 6. Comparison of IGF-1 expression in HCECs between AMCMs
from cryopreserved and live AM. Twelve hours after serum and growth
factor starvation, the medium was exchanged with the serum-free
DMEM, 50 L/mL AMCM from live-AM, or 50 L/mL AMCM from
cryopreserved AM (CryoP AM), followed by incubation for 12 hours.
The cell lysate was processed by 8% SDS-PAGE and transferred to PVDF
membrane, followed by immunoblot analysis with IGF-1 antibody.
FIGURE 7. The effect of IGF-1 on HCEC proliferation and DNA syn-
thesis. Before IGF-1 treatment, cells were serum starved for 12 hours.
At 24 hours after treatment with 10 or 50 ng/mL IGF-1, cell prolifera-
tion was significantly increased in cells treated with 10 ng/mL IGF-1
and was two times higher than in the serum-free control cells treated
with 50 ng/mL IGF-1 (*P  0.05, compared with the control; A). The
DNA synthesis was also increased by IGF-1 treatment in a dose-depen-
dent manner (B). The data are representative of results in three exper-
iments, each performed in triplicate.
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HCEC Proliferation Inhibition Assay Using
Neutralizing Anti-IGF-1 Antibody and IGF-1 siRNA
To determine further the role of IGF-1 induction in AMCM-
induced HCEC proliferation, we used neutralizing anti IGF-1
antibody and also designed IGF-1 siRNA to interfere with IGF-1
mRNA. Before AMCM treatment, HCECs were treated with the
neutralizing antibody for 1 hour. For the IGF-1 siRNA assay, the
cells were transfected with IGF-1 siRNA and then treated with
AMCM for 24 hours. Consistent with the results described
earlier, cell proliferation increased in HCECs treated with
AMCM in the absence of either neutralizing anti IGF-1 antibody
or IGF-1 siRNA. However, AMCM-induced HCEC proliferation
was inhibited with neutralizing anti-IGF-1 antibody or in cells
transfected with IGF-1 siRNA (Fig. 8). This result suggests that
suppression of either IGF-1 by neutralizing antibody or gene
expression by IGF-1 siRNA effectively inhibited AMCM-induced
HCEC proliferation.
Akt Phosphorylation after Treatment with AMCM
and IGF-1 siRNA
Because Akt is a known downstream effector molecule of the
IGF-1 signaling pathway, we next investigated the effects of
AMCM and IGF-1 siRNA on Akt phosphorylation in HCECs. Akt
phosphorylation was increased in HCECs after AMCM treat-
ment (Fig. 9). This phosphorylation peaked at 12 hours and
then decreased in intensity over time. The total amount of Akt,
however, did not change over time.
The inhibitory effects of IGF-1 siRNA on Akt phosphoryla-
tion was confirmed by Western immunoblot after IGF-1 siRNA
treatment. Akt phosphorylation decreased in HCECs trans-
fected with siRNA-1, but not in control cells (Fig. 9). Specifi-
cally, transfection with siRNA-1 resulted in a 70% reduction
in Akt phosphorylation compared with the control. Based on
these data, we believe that AMCM-induced HCEC proliferation
is mediated by both IGF-1 production and Akt phosphoryla-
tion.
DISCUSSION
In our study in HCECs, (1) addition of AMCM to serum-free
medium significantly increased cell proliferation; (2) AMCM
induced production of IGF-1; (3) neutralizing IGF-1 with anti
IGF-1 antibody or IGF-1 siRNA inhibited the increase in cell
proliferation; and (4) AMCM-induced IGF-1 expression stimu-
lated phosphorylation of Akt. Taken together, these results
suggest that AM-facilitated in vitro HCEC proliferation may at
least in part be due to IGF-1 induction via unknown factors
present in the AM.
Human AM is now widely used to reconstruct the ocular
surface for the treatment of several conditions, including in-
tractable epithelial defects, chemical burns, partial limbal cell
deficiencies, ocular cicatricial pemphigoid, and Stevens-John-
son syndrome.19–22 In addition, AM is used to enhance in vitro
corneal epithelial cell culture systems.23 However, precisely
how AM promotes epithelialization, both in vivo and in vitro,
has not yet been elucidated. Some hypotheses propose that AM
facilitates epithelialization in the basement-membrane–like ac-
tion and mechanical protection from lid movement and that it
serves as a dressing material.19,24,25 In addition to these func-
tions, fresh or frozen AM has been shown to express many
growth factors, including EGF, HGF, and KGF, primarily in the
epithelial layer.15,26 Moreover, Touhami et al.16 reported that
NGF is an important factor in AM-facilitated corneal epithelial
FIGURE 9. Changes in Akt phosphorylation in HCECs after AMCM
and/or IGF-1 siRNA treatment (lane 1: control, serum-free medium;
lane 2: 10 L/mL AMCM; lane 3: 100 nM IGF-1 siRNA only; lane 4: 100
nM siRNA10 L/mL AMCM). One hour after AMCM treatment, Akt
phosphorylation was increased. However, this enhanced pAkt expres-
sion decreased after IGF-1 siRNA treatment.
FIGURE 8. Inhibitory effect of neutralizing anti-IGF-1 antibody and
IGF-1 siRNA on AMCM-induced HCEC proliferation. One hour before
treatment with 50 L/mL AMCM, 10 ng/mL neutralizing anti-IGF-1
antibody was added. For IGF-1 siRNA, the cells were incubated with
100 nM IGF-1 siRNA for 16 hours before AMCM treatment. Cell pro-
liferation was evaluated with the MTT assay at 24 hours after AMCM
treatment. AMCM-induced HCEC proliferation was significantly inhib-
ited by 10 ng/mL anti IGF-1 antibody and IGF-1 siRNA.
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cell migration. Their data helped explain why AM transplanta-
tion is effective in the healing of neurotrophic ulcer. However,
few studies have investigated the role of cytokines, which may
be released from the AM and may thereby affect cell prolifer-
ation and migration. In the present study, we used AMCM,
which is a medium that contains the releasable factors from
AMs. It may be possible to use AMCM to evaluate the effects of
AM cytokines on cell proliferation and migration and to ex-
clude physical effects of AM that may occur when it is applied
to the in vivo cornea.
To clarify the existence of putative factors in AMCM that
can induce IGF-1, we compared the effect of the AMCM from
either live or cryopreserved AM. AMCM from either live AM or
cryopreserved AM induced IGF-1. Also, densitometry for IGF-1
did not show a significant difference. Considering that no
viable cells were found after the cryopreservation of AM,27 the
IGF-1-inducible factors from AMCM may already exist in AM
itself, and may not be released by live cells in AM. However,
the AMCM from the AM that had been cryopreserved for more
than 3 months did not induce any IGF-1 (data not shown).
Taken together, the IGF-1-inducible factors may exist in AM
matrix and can be degraded when the cryopreservation of AM
is prolonged.
We can speculate that Akt is involved in IGF-1 induction by
AMCM. Activation of the IGF-1 receptor (IGF-1R) by IGF-1 is
known to result in phosphorylation of PI3-K and Akt, which
are known as cell proliferation and antiapoptotic effector mol-
ecules.28,29 Accordingly, in the current study, AMCM-induced
Akt activation was inhibited by IGF-1 siRNA. These results
suggest that IGF-1-induced HCEC proliferation may be medi-
ated by Akt phosphorylation. Also, because NGF signaling,
which as reported by Touhami et al.,16 is known to trigger the
downstream of the Akt pathway, it remains unknown whether
the NGF pathway is responsible for upregulating IGF-1 gene
expression.
We have not been able to elucidate fully how AMCM appli-
cation induces cell proliferation. Despite the fact that growth
hormone (GH) is known to induce IGF-1 and that the GH-IGF
axis is essential for cell proliferation, IGF-1 induction mecha-
nisms have not yet been identified in most cell types.30,31
Because of the central role of IGF-1 in cell migration and
proliferation in the wound-healing process, further studies
designed to elucidate how IGF-1 is induced in this process
should be performed. Also, we used HCECs expanded on a
cell-migration (Transwell; Corning-Costar) culture system with
3T3 fibroblasts as the feeder layer. The serum-free conditioned
medium collected from 3T3 fibroblasts is well known to con-
tain IGF-1.32 Although we used only the fibroblast feeder dur-
ing the cell-expansion period, to increase cell mass for prepar-
ing the experiments, and did not use the fibroblast feeder
during the proliferation and immunoblot assays, it is possible
that the IGF-1 from the fibroblast feeder already existed in the
experimental condition. However, the Western blot analysis in
the control group of our study showed a small amount IGF-1
expression in this situation. Therefore, we thought the effect
of IGF-1 produced by 3T3 fibroblasts might be minimal, if any,
in our experimental condition, even though such precondi-
tioning of human corneal epithelial cells may have set the stage
for them to be more dependent on IGF-1.
In conclusion, we have shown that AMCM can facilitate
HCEC proliferation via induction of IGF-1. These results sug-
gest that AMCM-induced IGF-1 induction may be an important
modulator of corneal epithelial healing by AM. Further in vitro
and in vivo studies are needed to investigate how AMCM
induces IGF-1 in HCECs and what factors and intracellular
signaling cascades are involved in the IGF-1 induction and cell
proliferation processes in HCECs.
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